Sclerosing agents in the management of lymphatic malformations in children: A systematic review
Topic overview
Systematic review of 886 pediatric patients across 48 studies found sclerotherapy achieved 89% success for lymphatic malformations, with macrocystic lesions responding better than microcystic variants. Doxycycline, bleomycin, and OK-432 showed high resolution rates for head/neck lesions, though OK-432 carried higher major complication risk including airway compromise.
Key takeaways
- Macrocystic lymphatic malformations respond significantly better to sclerotherapy than microcystic variants (89% vs 34% resolution, p<0.01)
- Doxycycline and bleomycin show high complete regression rates (85% and 91%) for head/neck lesions with lower complication profiles than OK-432
- OK-432 remains widely used despite lack of federal approval but carries higher risk of major complications including airway compromise
- Overall sclerotherapy success rate is 89% across agents, with low complication rates when appropriately selected for lesion type
- Microcystic disease shows modest response to sclerotherapy (34% resolution), suggesting need for alternative treatment strategies
Comments